Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verona Pharma Plc (VRNA)
NASDAQ:VRNA
Holding VRNA?
Track your performance easily
VRNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.39 - $23.07
Previous Close$20.82
Volume1.98M
Average Volume (3M)1.20M
Market Cap
$1.69B
Enterprise Value$1.47B
Total Cash (Recent Filing)$271.77M
Total Debt (Recent Filing)$51.33M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 06, 2024EPS Estimate
-$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding81,081,772
10 Day Avg. Volume1,296,558
30 Day Avg. Volume1,203,105
Standard Deviation0.24
R-Squared0.00568
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)4.45
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-11.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-28.79
Forecast
1Y Price Target
$35.80Price Target Upside66.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Verona Pharma News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VRNA FAQ
What was Verona Pharma Plc’s price range in the past 12 months?
Verona Pharma Plc lowest stock price was $11.39 and its highest was $23.07 in the past 12 months.
What is Verona Pharma Plc’s market cap?
Currently, no data Available
When is Verona Pharma Plc’s upcoming earnings report date?
Verona Pharma Plc’s upcoming earnings report date is Aug 06, 2024 which is 93 days ago.
How were Verona Pharma Plc’s earnings last quarter?
Verona Pharma Plc released its earnings results on May 09, 2024. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of -$0.03 by -$0.01.
Is Verona Pharma Plc overvalued?
According to Wall Street analysts Verona Pharma Plc’s price is currently Undervalued.
Does Verona Pharma Plc pay dividends?
Verona Pharma Plc does not currently pay dividends.
What is Verona Pharma Plc’s EPS estimate?
Verona Pharma Plc’s EPS estimate is -$0.05.
How many shares outstanding does Verona Pharma Plc have?
Verona Pharma Plc has 81,081,770 shares outstanding.
What happened to Verona Pharma Plc’s price movement after its last earnings report?
Verona Pharma Plc reported an EPS of -$0.04 in its last earnings report, missing expectations of -$0.03. Following the earnings report the stock price went down -0.874%.
Which hedge fund is a major shareholder of Verona Pharma Plc?
Among the largest hedge funds holding Verona Pharma Plc’s share is RA Capital Management. It holds Verona Pharma Plc’s shares valued at 102M.
---
Verona Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.80 (66.51% Upside)
$35.80 (66.51% Upside)
Blogger Sentiment
Bullish
VRNA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 354.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.9%
Last 30 Days ▲ 21.2%
Last 30 Days ▲ 21.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.80%
12-Months-Change
Fundamentals
Return on Equity
-25.30%
Trailing 12-Months
Asset Growth
-10.28%
Trailing 12-Months
Company Description
Verona Pharma Plc
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
---
VRNA Earnings Call
Q1 2024
0:00 / 0:00
---
VRNA Stock 12 Month Forecast
Average Price Target
$35.80
▲(66.51% Upside)
Technical Analysis
Kala Pharmaceuticals
―
Kodiak Sciences
―
Mersana Therapeutics
―
Minerva Neurosciences
―
Best Analysts Covering VRNA
1 Year
1 Year Success Rate
11/14 ratings generated profit
1 Year Average Return
+105.70%
assigned a buy rating 4 months ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +105.70% per trade.
---